Cellectar Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
CLRB$1.25+8.7%Stored close · as of Nov 6, 2026
Contents
Table of Contents
| Forward-Looking Statements | 2 | |
| PART I | 4 | |
|---|---|---|
| Item 1. | Business | 4 |
| Item 1A. | Risk Factors | 37 |
| Item 1B. | Unresolved Staff Comments | 64 |
| Item 1C. | Cybersecurity | 64 |
| Item 2. | Properties | 64 |
| Item 3. | Legal Proceedings | 64 |
| Item 4. | Mine Safety Disclosures | 64 |
| PART II | 65 | |
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 65 |
| Item 6. | Reserved | 65 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 65 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 69 |
| Item 8. | Financial Statements | 70 |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 94 |
| Item 9A. | Controls and Procedures | 94 |
| Item 9B. | Other Information | 96 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 96 |
| PART III | 97 | |
| Item 10. | Directors, Executive Officers, and Corporate Governance | 97 |
| Item 11. | Executive Compensation | 97 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 101 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 102 |
| Item 14. | Principal Accounting Fees and Services | 102 |
| PART IV | 103 | |
| Item 15. | Exhibits, Financial Statement Schedules | 103 |
| Item 16. | Summary | 105 |
| Signatures | 106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.